Alternatively, the observations that JAK-STAT inhibitors are currently in use in the clinical setting as antitumor therapeutics (48, 49) suggest that FBXO45 activation might interact with other yet unknown clients to induce cell proliferation linked to JAK-STAT1 activation that impact development of cancer. The gene discussed is STAT1; the disease is cancer.